(Q35491177)

8 August 2017

title

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity (English)

1 reference

8 August 2017

1 reference

11

Linda T Vahdat

1 reference

8 August 2017

9

Tessa Cigler

1 reference

8 August 2017

Sasha E Stanton

1

1 reference

8 August 2017

Maureen M Ward

2

1 reference

8 August 2017

Paul Christos

3

1 reference

8 August 2017

Rachel Sanford

4

1 reference

8 August 2017

Christina Lam

5

1 reference

8 August 2017

Marta V Cobham

6

1 reference

8 August 2017

Diana Donovan

7

1 reference

8 August 2017

Ronald J Scheff

8

1 reference

8 August 2017

Anne Moore

10

1 reference

8 August 2017

Maureen E Lane

12

1 reference

8 August 2017

Ellen Chuang

13

1 reference

8 August 2017

language of work or name

English

0 references

publication date

11 April 2015

1 reference

8 August 2017

1 reference

8 August 2017

volume

15

1 reference

8 August 2017

page(s)

267

1 reference

Creative Commons Attribution 4.0 International

8 August 2017

copyright license

start time

11 April 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4403678

Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4403678

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4403678

The pharmacogenetics research network: from SNP discovery to clinical drug response.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4403678

Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4403678

Cardiac dysfunction in the trastuzumab clinical trials experience

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4403678

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4403678

Requirement for neuregulin receptor erbB2 in neural and cardiac development

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4403678

Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4403678

Polymorphic Ala-allele carriers at residue 1170 of HER2 associated with Parkinson's disease.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4403678

HER2 Ile655Val polymorphism contributes to breast cancer risk: evidence from 27 case-control studies

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4403678

A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4403678

The HER2 I655V polymorphism and breast cancer risk in Ashkenazim

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4403678

ErbB2 is essential in the prevention of dilated cardiomyopathy.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4403678

Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4403678

The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25885598

12 December 2020

inferred from PubMed ID database lookup

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25885598

12 December 2020

inferred from PubMed ID database lookup

Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25885598

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1186/S12885-015-1298-6

1 reference

Dimensions Publication ID

8 August 2017

1011645681

0 references

Fatcat ID

release_is3rkkmmdrfjjfkmnsdu4hifmy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/is3rkkmmdrfjjfkmnsdu4hifmy

24 November 2022

mapped directly with Wikidata item

PMC publication ID

4403678

1 reference

8 August 2017

1 reference